Intravenous treatment with MK-3402 can be an effective strategy in fighting antimicrobial resistance

FHS
June 18, 2023
3:59 pm

New research by investigators in Ghent, Belgium shows that intravenous treatment with MK-3402, a metallo-beta-lactamase inhibitor, can be an effective strategy in fighting antimicrobial resistance. The findings are presented at ASM Microbe 2023, the annual meeting of the American Society for Microbiology.

Advamed CEO congratulates Trump, stresses need for public policy support

Advamed CEO Scott Whitaker congratulated President-elect Donald Trump on Friday for winning a second term and stressed the need for public policy to support innovation

November 11, 2024

Exclusive: A small San Diego biotech wants to change how Parkinson’s disease is diagnosed

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 9, 2024

Impact of early COVID-19 job loss on later mental health uncovered

How income or job loss during the initial phases of the coronavirus disease 2019 (COVID-19) pandemic is linked to subsequent psychological distress.

August 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.